Literature DB >> 34654977

Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.

Makoto Naoi1, Wakako Maruyama2, Masayo Shamoto-Nagai2.   

Abstract

Parkinson's disease is characterized by typical motor symptoms, loss of dopamine neurons in the substantia nigra, and accumulation of Lewy body composed of mutated α-synuclein. However, now it is considered as a generalized disease with multiple pathological features. Present available treatments can ameliorate symptoms at least for a while, but only a few therapies could delay progressive neurodegeneration of dopamine neurons. Lewy body accumulates in peripheral tissues many years before motor dysfunction becomes manifest, suggesting that disease-modifying therapy should start earlier during the premotor stage. Long-termed regulation of lifestyle, diet and supplement of nutraceuticals may be possible ways for the disease-modification. Diet can reduce the incidence of Parkinson's disease and phytochemicals, major bioactive ingredients of herbs and plant food, modulate multiple pathogenic factors and exert neuroprotective effects in preclinical studies. This review presents mechanisms underlying neuroprotection of phytochemicals against neuronal cell death and α-synuclein toxicity in Parkinson's disease. Phytochemicals are antioxidants, maintain mitochondrial function and homeostasis, prevent intrinsic apoptosis and neuroinflammation, activate cellular signal pathways to induce anti-apoptotic and pro-survival genes, such as Bcl-2 protein family and neurotrophic factors, and promote cleavage of damaged mitochondria and α-synuclein aggregates. Phytochemicals prevent α-synuclein oligomerization and aggregation, and dissolve preformed α-synuclein aggregates. Novel neuroprotective agents are expected to develop based on the scaffold of phytochemicals permeable across the blood-brain-barrier, to increase the bioavailability, ameliorate brain dysfunction and prevent neurodegeneration.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Mitochondria; Neuroprotection; Parkinson’s disease; Phytochemicals; α-Synuclein

Mesh:

Substances:

Year:  2021        PMID: 34654977     DOI: 10.1007/s00702-021-02427-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.850


  101 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

2.  EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.

Authors:  Jan Bieschke; Jenny Russ; Ralf P Friedrich; Dagmar E Ehrnhoefer; Heike Wobst; Katja Neugebauer; Erich E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

3.  Dietary habits and neurological features of Parkinson's disease patients: Implications for practice.

Authors:  Michela Barichella; Emanuele Cereda; Erica Cassani; Giovanna Pinelli; Laura Iorio; Valentina Ferri; Giulia Privitera; Marianna Pasqua; Angela Valentino; Fatemeh Monajemi; Serena Caronni; Caterina Lignola; Chiara Pusani; Carlotta Bolliri; Samanta A Faierman; Alessandro Lubisco; Giuseppe Frazzitta; Maria L Petroni; Gianni Pezzoli
Journal:  Clin Nutr       Date:  2016-07-05       Impact factor: 7.324

4.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Authors:  A Ascherio; S M Zhang; M A Hernán; I Kawachi; G A Colditz; F E Speizer; W C Willett
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

5.  Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils.

Authors:  Mustafa T Ardah; Katerina E Paleologou; Guohua Lv; Sindhu A Menon; Salema B Abul Khair; Jia-Hong Lu; Bared Safieh-Garabedian; Abdulmonem A Al-Hayani; David Eliezer; Min Li; Omar M A El-Agnaf
Journal:  Neurobiol Dis       Date:  2014-11-15       Impact factor: 5.996

Review 6.  Ginsenoside Rb1 as a neuroprotective agent: A review.

Authors:  Touqeer Ahmed; Syed Hammad Raza; Afifa Maryam; William N Setzer; Nady Braidy; Seyed Fazel Nabavi; Marcos Roberto de Oliveira; Seyed Mohammad Nabavi
Journal:  Brain Res Bull       Date:  2016-04-06       Impact factor: 4.077

Review 7.  Neuroprotective action of resveratrol.

Authors:  Stéphane Bastianetto; Caroline Ménard; Rémi Quirion
Journal:  Biochim Biophys Acta       Date:  2014-10-02

8.  Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein.

Authors:  Nuzhat Ahsan; Satyendra Mishra; Manish Kumar Jain; Avadhesha Surolia; Sarika Gupta
Journal:  Sci Rep       Date:  2015-05-18       Impact factor: 4.379

Review 9.  GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.

Authors:  Roger A Barker; Anders Bjorklund; Don M Gash; Alan Whone; Amber Van Laar; Jeffrey H Kordower; Krystof Bankiewicz; Karl Kieburtz; Mart Saarma; Sigrid Booms; Henri J Huttunen; Adrian Kells; Massimo S Fiandaca; A Jon Stoessl; David Eidelberg; Howard Federoff; Merja Voutilainen; David T Dexter; Jamie Eberling; Patrik Brundin; Lyndsey Isaacs; Leah Mursaleen; Eros Bresolin; Camille Carroll; Alasdair Coles; Brian Fiske; Helen Matthews; Codrin Lungu; Richard K Wyse; Simon Stott; Anthony E Lang
Journal:  J Parkinsons Dis       Date:  2020-06-03       Impact factor: 5.568

Review 10.  Resveratrol Derivatives as Potential Treatments for Alzheimer's and Parkinson's Disease.

Authors:  Bruno Dutra Arbo; Corinne André-Miral; Raif Gregorio Nasre-Nasser; Lúcia Emanueli Schimith; Michele Goulart Santos; Dennis Costa-Silva; Ana Luiza Muccillo-Baisch; Mariana Appel Hort
Journal:  Front Aging Neurosci       Date:  2020-04-17       Impact factor: 5.750

View more
  2 in total

1.  Neuroprotective Effects of Phytochemicals against Aluminum Chloride-Induced Alzheimer's Disease through ApoE4/LRP1, Wnt3/β-Catenin/GSK3β, and TLR4/NLRP3 Pathways with Physical and Mental Activities in a Rat Model.

Authors:  Ahmed Mohsen Elsaid Hamdan; Fatimah Hussain J Alharthi; Ahmed Hadi Alanazi; Soad Z El-Emam; Sameh S Zaghlool; Kamel Metwally; Sana Abdulaziz Albalawi; Yahia S Abdu; Reda El-Sayed Mansour; Hoda A Salem; Zakaria Y Abd Elmageed; Karema Abu-Elfotuh
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-17

Review 2.  Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.